clinical trial · NCT07620561
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
University of Maryland, Baltimore·phase2·not yet recruiting·n = 15
Prurigo Nodularis (PN)Lebrikizumab
brief summary
The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).
started
Sep 1, 2026
primary completion
Dec 1, 2027
completion
Mar 1, 2028
last updated
Sep 3, 2026
detailed description
This study is a Phase II, single center, open-label, single-arm clinical trial. Study participation will last up to 32 weeks, including a 4-week screening period, a 24-week treatment period with all participants receiving lebrikizumab injections, and a 4-week safety follow up period.
official title
Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients: A 24-Week Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol